- Home
- NUKK vs NLSP Comparison
NUKK vs NLSP Comparison
Compare NUKK & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUKK
- NLSP
- Stock Information
- Founded
- NUKK 2013
- NLSP 2015
- Country
- NUKK United States
- NLSP Switzerland
- Employees
- NUKK N/A
- NLSP N/A
- Industry
- NUKK Blank Checks
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- NUKK Finance
- NLSP Health Care
- Exchange
- NUKK Nasdaq
- NLSP Nasdaq
- Market Cap
- NUKK 4.8M
- NLSP 5.2M
- IPO Year
- NUKK N/A
- NLSP 2021
- Fundamental
- Price
- NUKK $50.79
- NLSP $2.00
- Analyst Decision
- NUKK
- NLSP
- Analyst Count
- NUKK 0
- NLSP 0
- Target Price
- NUKK N/A
- NLSP N/A
- AVG Volume (30 Days)
- NUKK 11.1M
- NLSP 450.1K
- Earning Date
- NUKK 12-31-2024
- NLSP 12-31-2024
- Dividend Yield
- NUKK N/A
- NLSP N/A
- EPS Growth
- NUKK N/A
- NLSP N/A
- EPS
- NUKK N/A
- NLSP N/A
- Revenue
- NUKK $10,752,616.00
- NLSP N/A
- Revenue This Year
- NUKK N/A
- NLSP N/A
- Revenue Next Year
- NUKK N/A
- NLSP N/A
- P/E Ratio
- NUKK N/A
- NLSP N/A
- Revenue Growth
- NUKK N/A
- NLSP N/A
- 52 Week Low
- NUKK $1.30
- NLSP $1.73
- 52 Week High
- NUKK $67.77
- NLSP $24.32
- Technical
- Relative Strength Index (RSI)
- NUKK 98.34
- NLSP 22.65
- Support Level
- NUKK $1.34
- NLSP $1.75
- Resistance Level
- NUKK $1.60
- NLSP $2.13
- Average True Range (ATR)
- NUKK 4.90
- NLSP 0.29
- MACD
- NUKK 3.54
- NLSP -0.03
- Stochastic Oscillator
- NUKK 74.44
- NLSP 4.23
About NUKK Nukkleus Inc.
Nukkleus Inc is a financial technology company that is focused on providing software and technology solutions. The company's operating segment includes General support services and Financial services. General support services include providing software, technology, customer sales and marketing, and risk management technology hardware and software solutions package under a GSA to a related party. Financial services include providing payment services from one fiat currency to another or to digital assets. It generates maximum revenue from the General support services segment. Geographically, the majority of its revenue is generated from the United Kingdom and the rest from the United States and Malta.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.